Your account is not claimed yet. You can sign up with ORCID to claim your account.

Matthew Gumbleton

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 7

Top Venues

BMC research notes

Science signaling

University of Utah

SUNY Upstate Medical University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Utah Jun 24o 2017

United States

Resident :: Medicine

Education History

SUNY Upstate Medical University Jun 1o 2009 - May 24o 2017

United States

PHD

Publications

Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Matthew Gumbleton, Raki Sudan, Sandra Fernandes, Robert W Engelman, Christopher M Russo, John D Chisholm, William G Kerr
Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival. Science signaling 10 (500) (2017)

Matthew Gumbleton.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Matthew Gumbleton